Recent Updates
Recently added Catalysts
RCEL Negative Sentiment Score: 25/100

AVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating AVITA Medical, Inc. on behalf of its stockholders concerning potential violations of federal securities laws. This comes in light of Avita's recent financial results which revealed a backlog of unpaid provider claims impacting the use of its Recell product. The failure to adjudicate claims in a timely manner has led to decreased demand and uncertainty among providers. Following these disclosures, Avita's stock experienced a significant decline in value.

Market Sentiment Analysis

CONCERNS & RISKS

  • Avita is under investigation for potential violations of federal securities laws.
  • The company's second quarter 2025 financial results revealed a significant backlog of unpaid claims affecting Recell procedures.
  • There has been a reduction in Recell utilization due to uncertainty among providers regarding payment timelines.
  • The stock price dropped approximately 21% following the financial results disclosure.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ:RCEL) on behalf of Avita stockholders. Our investigation concerns whether Avita has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On August 7, 2025, Avita released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.” The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company’s wound care product, Recell, “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.” As a result, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.”
On this news, the price of AVITA’s shares declined by $1.13 per share, or approximately 21%, from $5.38 per share on August 7, 2025 to close at $4.25 on August 8, 2025.
If you purchased or otherwise acquired Avita shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should I contact regarding Avita stock losses?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire.

What caused the drop in Avita's share price?

Avita's share price fell due to a backlog in unpaid provider claims.

When did Avita announce its financial results?

Avita released its second quarter 2025 financial results on August 7, 2025.

Is there a cost for consulting about Avita claims?

There is no cost or obligation for discussing your options with the firm.

How can I learn more about my rights as an Avita shareholder?

Contact Brandon Walker or Marion Passmore via email or phone for assistance.

Last updated: Sep 25, 2025